Exposure during infancy was associated with increased risk up to 16 years of age, especially for nonallergic disease.
Allergic rhinitis is the twelfth most common diagnosis made at family physician visits.
Researchers measured rates of childhood allergic conditions with data from healthcare provider-based diagnoses.
Corticosteroids may relieve symptoms of allergic rhinitis, but are not always appropriate.
Significant improvements were found in allergen immunotherapy for local allergic rhinitis.
This spring may bring another bad pollen season, but clinicians can help their patients cope with allergies by using tips from the ACAAI.
Patients with prevalent allergic rhinitis are 3 times more likely to develop asthma or mental health related comorbidities.
A 38-year-old man presents to an otolaryngology clinic with itchy eyes, periorbital swelling, and an itchy red rash on his face and arms.
Although, because pollen season started later this year, pollen season may be shorter than in past years, according to allergy experts.
Symptoms and laboratory parameters of allergic disease exhibit prominent circadian variations, with symptoms worsening overnight or early in the morning.
Gas, dust, and fume exposure correlated with a doubled risk of sensitization to mites, but not other allergens.
No serious local allergic swellings or serious allergic reactions among SLIT-tablet-treated individuals with asthma.
In utero, infant exposure to tobacco smoke has been linked to increased to asthma, rhinitis risk in early childhood and eczema in later life.
Inappropriate use in children under 15 years old and patients seeking relief for asthma cited as top concerns.
Ragwitek is the third sublingual immunotherapy (SLIT) the agency approved for allergies this month, after Merck's Grastek and Greer's OralAir.
Association toward decreased odds of allergy among children of mother's whose allergic rhinitis was treated with immunotherapy.
The ability to differentiate between the allergic and nonallergic form of these conditions is crucial when determining treatment.
Zetonna is a nasal aerosol approved to treat both ocular and nasal symptoms associated with seasonal allergic rhinitis (SAR), and nasal symptoms associated with perennial allergic rhinitis (PAR) in adults and adolescents aged >12 years.
The FDA has approved azelastine HCl and fluticasone propionate nasal spray (Dymista, Meda) to treat seasonal allergic rhinitis.
Knowing when to prescribe antibiotics and what kind to give is crucial. Here are some guidelines for patients with mild-to-moderate infections.
What is the treatment protocol for a patient with rhus dermatitis in one eye?
Butterbur, once discouraged because of its potential to cause liver damage, is now widely used in Europe to combat allergic rhinitis, asthma, and migraine.
Managing the condition involves allergen avoidance, pharmacologic therapy, and immunotherapy. Here is guidance on each of these steps.